B-intervention	0	10	Autologous
I-intervention	11	15	bone
I-intervention	16	22	marrow
I-intervention	23	30	stromal
I-intervention	31	36	cells
I-intervention	37	52	transplantation
O	53	56	for
O	57	60	the
O	61	70	treatment
O	71	73	of
O	74	83	secondary
O	84	87	arm
O	88	98	lymphedema
O	98	99	:
O	100	101	a
O	102	113	prospective
O	114	124	controlled
O	125	130	study
O	131	133	in
O	134	142	patients
O	143	147	with
O	148	154	breast
O	155	161	cancer
O	162	169	related
O	170	180	lymphedema
O	180	181	.

O	182	184	To
O	185	194	determine
O	195	198	the
O	199	204	short
O	204	205	-
O	206	209	and
O	210	214	long
O	214	215	-
O	215	219	term
O	220	226	effect
O	227	229	of
O	230	234	bone
O	235	241	marrow
O	242	249	stromal
O	250	255	cells
O	256	257	(
O	257	262	BMSCs
O	262	263	)
O	264	279	transplantation
O	280	282	as
O	283	284	a
O	285	294	treatment
O	295	298	for
O	299	305	breast
O	306	312	cancer
O	312	313	-
O	313	320	related
O	321	331	lymphedema
O	331	332	.

O	333	335	To
O	336	344	contrast
O	345	347	it
O	348	352	with
O	353	360	complex
O	361	373	decongestive
O	374	387	physiotherapy
O	388	389	(
O	389	392	CDT
O	392	393	)
O	393	394	.

B-intervention-participants	395	402	Fifteen
B-eligibility	403	408	women
I-eligibility	409	413	with
I-eligibility	414	424	lymphedema
I-eligibility	424	425	,
I-eligibility	426	429	who
I-eligibility	430	433	had
I-eligibility	434	443	undergone
I-eligibility	444	450	breast
I-eligibility	451	457	cancer
I-eligibility	458	465	surgery
I-eligibility	466	469	and
I-eligibility	469	470	/
I-eligibility	470	472	no
I-eligibility	473	485	radiotherapy
I-eligibility	486	487	5
I-eligibility	488	493	years
I-eligibility	494	500	before
O	500	501	,
O	502	508	served
O	509	511	as
O	512	515	the
O	516	528	experimental
O	529	534	group
O	535	538	and
O	539	547	received
O	548	552	BMSC
O	553	568	transplantation
O	568	569	;
B-control-participants	570	572	35
O	573	581	patients
O	582	586	were
O	587	595	measured
O	596	598	as
O	599	602	the
O	603	610	control
O	611	616	group
O	617	624	treated
O	625	629	with
B-control	630	633	CDT
O	633	634	.

O	635	639	They
O	640	644	were
O	645	649	kept
O	650	652	on
O	653	659	follow
O	659	660	-
O	660	662	up
O	663	666	for
O	667	668	1
O	669	673	year
O	673	674	.

O	675	678	Two
O	679	687	patients
O	688	690	in
O	691	694	the
O	695	698	CDT
O	699	704	Group
O	705	711	failed
O	712	714	to
O	715	719	keep
O	720	726	follow
O	726	727	-
O	727	729	up
O	729	730	.

B-outcome	731	737	Before
I-outcome	738	747	treatment
O	747	748	,
O	749	757	patients
O	758	761	had
B-outcome	762	769	average
I-outcome	770	776	volume
I-outcome	777	779	of
I-outcome	780	785	edema
O	786	788	in
O	789	792	the
O	793	801	affected
O	802	805	arm
O	806	808	of
B-iv-cont-mean	809	813	1166
I-iv-cont-mean	813	814	.
I-iv-cont-mean	814	815	2
I-iv-cont-mean	816	818	ml
O	819	821	in
O	822	826	BMSC
O	827	832	Group
O	833	836	and
B-cv-cont-mean	837	841	1091
I-cv-cont-mean	841	842	.
I-cv-cont-mean	842	843	0
I-cv-cont-mean	844	846	ml
O	847	849	in
O	850	853	the
O	854	857	CDT
O	858	863	Group
O	863	864	.

O	865	869	With
O	870	877	therapy
O	877	878	,
O	879	884	there
O	885	888	was
O	889	891	an
B-outcome	892	899	average
I-outcome	900	908	decrease
I-outcome	909	911	in
I-outcome	912	922	lymphedema
I-outcome	923	929	volume
O	930	932	of
B-iv-cont-mean	933	936	730
I-iv-cont-mean	936	937	.
I-iv-cont-mean	937	938	7
O	938	939	,
B-iv-cont-mean	940	943	887
I-iv-cont-mean	943	944	.
I-iv-cont-mean	944	945	9
O	946	949	and
B-iv-cont-mean	950	953	958
I-iv-cont-mean	953	954	.
I-iv-cont-mean	954	955	6
I-iv-cont-mean	956	958	ml
O	959	961	in
O	962	965	the
O	966	970	BMSC
O	971	976	Group
O	977	980	and
B-cv-cont-mean	981	984	714
I-cv-cont-mean	984	985	.
I-cv-cont-mean	985	986	8
O	986	987	,
B-cv-cont-mean	988	991	657
I-cv-cont-mean	991	992	.
I-cv-cont-mean	992	993	9
O	994	997	and
B-cv-cont-mean	998	1001	571
I-cv-cont-mean	1001	1002	.
I-cv-cont-mean	1002	1003	3
I-cv-cont-mean	1004	1006	ml
O	1007	1009	in
O	1010	1013	the
O	1014	1017	CDT
O	1018	1023	Group
B-outcome	1024	1029	after
I-outcome	1030	1031	1
I-outcome	1031	1032	,
I-outcome	1033	1034	3
I-outcome	1035	1038	and
I-outcome	1039	1041	12
I-outcome	1042	1048	months
O	1048	1049	,
O	1050	1062	respectively
O	1062	1063	.

B-outcome	1064	1070	Before
I-outcome	1071	1080	treatment
O	1080	1081	,
O	1082	1085	the
B-outcome	1086	1096	percentage
I-outcome	1097	1099	of
I-outcome	1100	1110	lymphedema
O	1111	1114	was
B-iv-cont-mean	1115	1117	28
I-iv-cont-mean	1117	1118	.
I-iv-cont-mean	1118	1119	6
I-iv-cont-mean	1119	1120	%
O	1121	1123	in
O	1124	1127	the
O	1128	1132	BMSC
O	1133	1138	Group
O	1139	1142	and
B-cv-cont-mean	1143	1145	26
I-cv-cont-mean	1145	1146	.
I-cv-cont-mean	1146	1147	8
I-cv-cont-mean	1147	1148	%
O	1149	1151	in
O	1152	1155	the
O	1156	1159	CDT
O	1160	1165	Group
O	1165	1166	.

B-outcome	1167	1172	After
I-outcome	1173	1182	treatment
O	1182	1183	,
O	1184	1189	there
O	1190	1193	was
O	1194	1195	a
O	1196	1204	decrease
O	1205	1207	of
B-iv-cont-mean	1208	1210	64
I-iv-cont-mean	1210	1211	.
I-iv-cont-mean	1211	1212	6
O	1212	1213	,
B-iv-cont-mean	1214	1216	78
I-iv-cont-mean	1216	1217	.
I-iv-cont-mean	1217	1218	5
O	1219	1222	and
B-iv-cont-mean	1223	1225	81
I-iv-cont-mean	1225	1226	.
I-iv-cont-mean	1226	1227	0
I-iv-cont-mean	1227	1228	%
O	1229	1231	in
O	1232	1235	the
O	1236	1240	BMSC
O	1241	1246	Group
O	1247	1250	and
B-cv-cont-mean	1251	1253	67
I-cv-cont-mean	1253	1254	.
I-cv-cont-mean	1254	1255	2
O	1255	1256	,
B-cv-cont-mean	1257	1259	60
I-cv-cont-mean	1259	1260	.
I-cv-cont-mean	1260	1261	4
O	1262	1265	and
B-cv-cont-mean	1266	1268	54
I-cv-cont-mean	1268	1269	.
I-cv-cont-mean	1269	1270	5
I-cv-cont-mean	1270	1271	%
O	1272	1274	in
O	1275	1278	the
O	1279	1282	CDT
O	1283	1288	Group
B-outcome	1289	1294	after
I-outcome	1295	1296	1
I-outcome	1296	1297	,
I-outcome	1298	1299	3
I-outcome	1300	1303	and
I-outcome	1304	1306	12
I-outcome	1307	1313	months
O	1313	1314	,
O	1315	1327	respectively
O	1327	1328	.

O	1329	1333	When
O	1334	1339	asked
O	1340	1342	to
O	1343	1351	quantify
O	1352	1364	subjectively
O	1365	1370	their
B-outcome	1371	1375	pain
O	1376	1378	on
O	1379	1380	a
O	1381	1388	numeric
O	1389	1394	scale
O	1395	1399	from
O	1400	1401	0
O	1402	1404	to
O	1405	1406	5
O	1406	1407	,
O	1408	1411	the
O	1412	1419	average
O	1420	1425	score
O	1426	1428	of
O	1429	1434	these
O	1435	1443	patients
O	1444	1447	was
B-iv-cont-mean	1448	1449	3
I-iv-cont-mean	1449	1450	.
I-iv-cont-mean	1450	1451	4
O	1452	1454	in
O	1455	1458	the
O	1459	1463	BMSC
O	1464	1469	group
O	1470	1473	and
B-cv-cont-mean	1474	1475	4
I-cv-cont-mean	1475	1476	.
I-cv-cont-mean	1476	1477	0
O	1478	1480	in
O	1481	1484	the
O	1485	1488	CDT
O	1489	1494	Group
O	1494	1495	.

O	1496	1499	The
B-outcome	1500	1507	average
I-outcome	1508	1513	score
O	1514	1517	was
O	1518	1525	reduced
O	1526	1528	to
B-iv-cont-mean	1529	1530	1
I-iv-cont-mean	1530	1531	.
I-iv-cont-mean	1531	1532	6
O	1532	1533	,
B-iv-cont-mean	1534	1535	0
I-iv-cont-mean	1535	1536	.
I-iv-cont-mean	1536	1537	8
O	1538	1541	and
B-iv-cont-mean	1542	1543	0
I-iv-cont-mean	1543	1544	.
I-iv-cont-mean	1544	1545	6
O	1546	1548	in
O	1549	1552	the
O	1553	1557	BMSC
O	1558	1563	Group
O	1564	1567	and
O	1568	1570	to
B-cv-cont-mean	1571	1572	1
I-cv-cont-mean	1572	1573	.
I-cv-cont-mean	1573	1574	2
O	1574	1575	,
B-cv-cont-mean	1576	1577	1
I-cv-cont-mean	1577	1578	.
I-cv-cont-mean	1578	1579	7
O	1580	1583	and
B-cv-cont-mean	1584	1585	1
I-cv-cont-mean	1585	1586	.
I-cv-cont-mean	1586	1587	6
O	1588	1590	in
O	1591	1594	CDT
O	1595	1600	Group
B-outcome	1601	1606	after
I-outcome	1607	1608	1
I-outcome	1608	1609	,
I-outcome	1610	1611	3
I-outcome	1612	1615	and
I-outcome	1616	1618	12
I-outcome	1619	1625	months
O	1625	1626	,
O	1627	1639	respectively
O	1639	1640	.

O	1641	1651	Autologous
O	1652	1657	BMSCs
O	1658	1673	transplantation
O	1674	1677	for
O	1678	1681	the
O	1682	1691	treatment
O	1692	1694	of
O	1695	1701	breast
O	1702	1708	cancer
O	1709	1716	related
O	1717	1727	lymphedema
O	1728	1730	is
O	1731	1740	effective
O	1741	1744	and
O	1745	1753	feasible
O	1753	1754	.
